Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)

被引：0

作者：

Nobuaki Suzuki

Shoichi Hazama

Takeshi Nagasaka

Hiroaki Tanioka

Yasuo Iwamoto

Yuji Negoro

Masami Yamauchi

Michiya Kobayashi

Hiroshi Okuda

Noriaki Fujishima

Taku Nishimura

Naoki Yamanaka

Kazuhiro Toyota

Yoshiko Mori

Yuki Nakagami

Mototsugu Shimokawa

Hiroaki Nagano

Masazumi Okajima

机构：

[1] Yamaguchi University Graduate School of Medicine,Department of Gastroenterological, Breast and Endocrine Surgery

[2] Yamaguchi University School of Medicine,Department of Translational Research and Developmental Therapeutics Against Cancer

[3] Kawasaki Medical School,Department of Clinical Oncology

[4] Hiroshima City Hiroshima Citizens Hospital,Department of Medical Oncology

[5] Kochi Health Sciences Center,Department of Medical Oncology

[6] Hiroshima Prefectural Hospital,Division of Clinical Oncology

[7] Kochi Medical School Hospital,Cancer Treatment Center

[8] Onomichi General Hospital,Surgery and Endoscopic Surgery

[9] Fukuda Clinic of Internal Medicine,Department of Surgery

[10] Heart and Digestive,Department of Surgery

[11] Kokura Memorial Hospital,Department of Surgery

[12] Japanese Red Cross Yamaguchi Hospital,Department of Surgery

[13] National Hospital Organization Higashihiroshima Medical Center,Department of Gastroenterological Surgery

[14] Okayama University Graduate School of Medicine,Cancer Biostatistics Laboratory, Clinical Research Institute

[15] Dentistry and Pharmaceutical Sciences,Department of Surgery

[16] National Kyushu Cancer Center,undefined

[17] Hiroshima City Hiroshima Citizens Hospital,undefined

来源：

International Journal of Clinical Oncology | 2019年 / 24卷

关键词：

Bevacizumab; CAPIRI; Biweekly; Second line; mCRC;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1223 / 1230

页数：7

共 50 条

[1] Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JS']JSWOG-C3 study)
Suzuki, Nobuaki
Hazama, Shoichi
Nagasaka, Takeshi
Tanioka, Hiroaki
Iwamoto, Yasuo
Negoro, Yuji
Yamauchi, Masami
Kobayashi, Michiya
Okuda, Hiroshi
Fujishima, Noriaki
Nishimura, Taku
Yamanaka, Naoki
Toyota, Kazuhiro
Mori, Yoshiko
Nakagami, Yuki
Shimokawa, Mototsugu
Nagano, Hiroaki
Okajima, Masazumi
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (10) : 1223 - 1230
[2] Multicenter phase II study of biweekly XELIRI plus bevacizumab as a second-line therapy in patients with metastatic colorectal cancer (JS']JSWOG-C3 study)
Mori, Y.
Suzuki, N.
Nagasaka, T.
Tanioka, H.
Iwamoto, Y.
Neki, Y.
Yamatsuji, T.
Kobayashi, M.
Nakajima, M.
Ojima, Y.
Ikeda, S.
Kawamoto, K.
Shinozaki, K.
Tsuji, A.
Hinoi, T.
Yamaguchi, Y.
Yamashita, K.
Shimokawa, M.
Okajima, M.
Hazama, S.
ANNALS OF ONCOLOGY, 2017, 28
[3] A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
Suenaga, Mitsukuni
Mizunuma, Nobuyuki
Matsusaka, Satoshi
Shinozaki, Eiji
Ozaka, Masato
Ogura, Mariko
Chin, Keisho
Yamaguchi, Toshiharu
DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 1653 - 1662
[4] Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy forMetastatic Colorectal Cancer
Louvet, C.
Andre, T.
Gamelin, E.
Hebbar, M.
Mabro, M.
Bennamoun, M.
Rassam, H.
de Gramont, A.
JOURNAL OF ONCOLOGY, 2010, 2010
[5] Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab
Hidekazu Kuramochi
Masayuki Ando
Michio Itabashi
Go Nakajima
Kazuyuki Kawakami
Mie Hamano
Eiichi Hirai
Hajime Yokomizo
Ryuji Okuyama
Tatsuo Araida
Kazuhiko Yoshimatsu
Shingo Kameoka
Kazuhiko Hayashi
Cancer Chemotherapy and Pharmacology, 2017, 79 : 579 - 585
[6] A phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and bevacizumab
Nakajima, Go
Kuramochi, Hidekazu
Ando, Masayuki
Itabashi, Michio
Kawakami, Kazuyuki
Hamano, Mie
Hirai, Eiichi
Lino, Takayuki
Yokomizo, Hajime
Okuyama, Ryuji
Araida, Tatsuo
Yoshimatsu, Kazuhiko
Kameoka, Shingo
Hayashi, Kazuhiko
CANCER RESEARCH, 2016, 76
[7] Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab
Kuramochi, Hidekazu
Ando, Masayuki
Itabashi, Michio
Nakajima, Go
Kawakami, Kazuyuki
Hamano, Mie
Hirai, Eiichi
Yokomizo, Hajime
Okuyama, Ryuji
Araida, Tatsuo
Yoshimatsu, Kazuhiko
Kameoka, Shingo
Hayashi, Kazuhiko
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (03) : 579 - 585
[8] Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study
Deng, Ting
Zhang, Le
Liu, Xiao-jian
Xu, Jian-ming
Bai, Yu-xian
Wang, Yan
Han, Yu
Li, Yu-hong
Ba, Yi
MEDICAL ONCOLOGY, 2013, 30 (04)
[9] Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study
Ting Deng
Le Zhang
Xiao-jian Liu
Jian-ming Xu
Yu-xian Bai
Yan Wang
Yu Han
Yu-hong Li
Yi Ba
Medical Oncology, 2013, 30
[10] Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy
Yong Sang Hong
Jeeyun Lee
Kyu-pyo Kim
Jae-Lyun Lee
Young Suk Park
Joon Oh Park
Se Hoon Park
Sun Young Kim
Ji Yeon Baek
Jee Hyun Kim
Keun-Wook Lee
Tae-You Kim
Tae Won Kim
Investigational New Drugs, 2013, 31 : 183 - 191

← 1 2 3 4 5 →